, Tracking Stock Market Picks
Enter Symbol:
Accelrys, Inc. (ACCL) [hlAlert]

up 50.54 %

Accelrys, Inc. (ACCL) rated Buy with price target $10 by Feltl & Co.

Posted on: Monday,  Mar 26, 2012  9:25 AM ET by Feltl & Co.

Feltl & Co. rated Buy Accelrys, Inc. (NASDAQ: ACCL) on 03/26/2012, when the stock price was $8.31. Since
then, Accelrys, Inc. has gained 50.54% as of 04/29/2014's recent price of $12.51.
If you would have followed this Feltl & Co.'s recommendation on ACCL, you would have gained 50.54% of your investment in 764 days.

Pharmacopeia is committed to discovering and developing novel therapeutics to address significant medical needs. The Company has a broad portfolio advancing toward clinical validation, both independently and with partners. Pharmacopeia's most advanced internal program is a dual-acting angiotensin and endothelin receptor antagonist for hypertension and diabetic kidney disease for which Phase 1 clinical trials are underway. Other internal proprietary programs address primarily immunoregulation. Pharmacopeia's collaborative efforts have resulted in a portfolio that includes one partnered program currently in Phase 2 clinical trials targeting chronic obstructive pulmonary disease and four partnered programs in Phase 1 clinical trials targeting rheumatoid arthritis, oncology, metabolic and inflammatory diseases. Four additional partnered compounds are in preclinical development.

Feltl and Company's Research Department is focused on micro to small market capitalization companies that are not widely covered by other research firms. Our research universe is focused and organized around the sectors of Technology, HealthCare, and Leisure/Consumer. Feltl and Company holds its research department to very high standards, and strives to provide value- added investment ideas through sound fundamental analysis. Feltl and Company's Research Department includes six senior analysts and one associate analyst with many years of investment analysis experience. Although we are focused on, and committed to, companies in the Upper Midwest, our reach extends from coast to coast. About half of the companies we cover are headquartered outside our "backyard." Our analysts have significant industry experience and strive to know their companies inside and out. Through stringent analysis, they provide value by creating a disciplined application of company valuation, allowing our clients to make sound investment decisions.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/26/2012 9:25 AM Buy
8.31 10.00
as of 12/31/2012
1 Week down  -4.13 %
1 Month up  2.72 %
3 Months up  4.50 %
1 YTD up  8.90 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy